Clinical Research Directory
Browse clinical research sites, groups, and studies.
How Long Should we Give Steroids for Patients With Severe PCP
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Summary
The HOW LONG trial is an international, multicenter, Phase IV randomized clinical trial evaluating the optimal duration of adjunctive systemic corticosteroids in immunocompromised adults with severe Pneumocystis jirovecii pneumonia (PCP) who demonstrate early clinical recovery. Participants who no longer require supplemental oxygen by day 10 of corticosteroid therapy are randomized to discontinue corticosteroids at day 10 (or hospital discharge, if earlier) versus continue corticosteroids for a total of 21 days. The trial assesses whether earlier discontinuation reduces steroid-related complications while maintaining clinical outcomes.
Official title: How Long Should we Give Steroids for Patients With Severe PCP (HOW LONG)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
416
Start Date
2026-01-30
Completion Date
2029-06
Last Updated
2026-01-09
Healthy Volunteers
No
Conditions
Interventions
Systemic corticosteroids
Adjunctive systemiccorticosteroid therapy administered as part of standard treatment for pneumocystis Pneumonia, with duration varying by study arm.
Locations (1)
McGill university Health Centre (Royal victoria Hospital and Montreal General Hospital
Montreal, Quebec, Canada